| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Cohort Study |
| Article Title |
Effects of SARS-CoV-2 infection on incidence and treatment strategies of hepatocellular carcinoma in people with chronic liver disease
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Lung-Yi Mak, Matthew Shing Hin Chung, Xue Li, Francisco Tsz Tsun Lai, Eric Yuk Fai Wan, Celine Sze Ling Chui, Franco Wing Tak Cheng, Esther Wai Yin Chan, Ching Lung Cheung, Ivan Chi Ho Au, Xi Xiong, Wai-Kay Seto, Man-Fung Yuen, Carlos King Ho Wong and Ian Chi Kei Wong |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| University Grants Committee |
C7154-20GF |
| Innovation and Technology Commission |
AIR@InnoHK |
| Data Discovery for Health (D24H) |
|
|
| Corresponding Author |
Carlos King Ho Wong, BSc, MPhil, PhD, Assistant Professor, Department of Pharmacology and Pharmacy, The University of Hong Kong, 2/F, 21 Sassoon Road, Li Ka Shing Faculty of Medicine, Laboratory Block, Faculty of Medicine Building, Hong Kong , China. carlosho@hku.hk |
| Key Words |
SARS-CoV-2 infection; Chronic liver disease; Long COVID; Post-COVID-19 syndrome; Cirrhosis; Hepatocellular carcinoma |
| Core Tip |
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in patients with chronic liver disease (CLD) leads to worse adverse clinical outcomes. In our study, we found that although CLD patients with SARS-CoV-2 infection did not have higher risk of developing liver cancer, they are more likely to receive palliative treatment for hepatocellular carcinoma, compared to CLD patients who did not have SARS-CoV-2 infection. Coronavirus disease 2019 also led to increased risks of all-cause mortality and adverse hepatic outcomes. These detrimental effects of SARS-CoV-2 infection were observed in both acute and post-acute phases among CLD patients. |
| Publish Date |
2024-02-27 11:58 |
| Citation |
Mak LY, Chung MSH, Li X, Lai FTT, Wan EYF, Chui CSL, Cheng FWT, Chan EWY, Cheung CL, Au ICH, Xiong X, Seto WK, Yuen MF, Wong CKH, Wong ICK. Effects of SARS-CoV-2 infection on incidence and treatment strategies of hepatocellular carcinoma in people with chronic liver disease. World J Hepatol 2024; 16(2): 211-228 |
| URL |
https://www.wjgnet.com/1948-5182/full/v16/i2/211.htm |
| DOI |
https://dx.doi.org/10.4254/wjh.v16.i2.211 |
